<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04826081</url>
  </required_header>
  <id_info>
    <org_study_id>2020/CHU/41</org_study_id>
    <nct_id>NCT04826081</nct_id>
  </id_info>
  <brief_title>Study on the Risks of Symptomatic Dengue on Pregnancy</brief_title>
  <acronym>ERiDenG</acronym>
  <official_title>Prospective Study on the Risks of Symptomatic Dengue on Pregnancy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de la Réunion</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de la Réunion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dengue fever is the most common arbovirus worldwide (390 million people infected per year)&#xD;
      and is a global public health problem. This public health problem is also becoming European&#xD;
      due to its rapid expansion over the past decade with an increase in cases of 400% and the&#xD;
      appearance of the first indigenous cases of dengue in Europe. Studies on the consequences of&#xD;
      dengue fever on pregnancy find contradictory results. In fact, most of these studies are&#xD;
      observational studies describing the risk of dengue fever for pregnancy, without comparison&#xD;
      with a control group or comparing the different pregnancy morbidities to those found during&#xD;
      pregnancy in the general population. Other research is retrospective case-control studies&#xD;
      with major biases in the definitions of obstetric complications, which makes the results&#xD;
      questionable.&#xD;
&#xD;
      The study therefore proposes to carry out a prospective case-control study with rigorous&#xD;
      matching criteria, strict definitions of cases, controls and obstetric complications.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 15, 2021</start_date>
  <completion_date type="Anticipated">March 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the difference in the proportion of intrauterine growth retardation (IUGR) between the Case group and the Control group</measure>
    <time_frame>at childbirth</time_frame>
    <description>Birth weight &lt;3rd percentile according to Sentinel Network Perinatal Database : AUDIPOG</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the difference in the proportion of prematurity between the case group and the control group</measure>
    <time_frame>at childbirth</time_frame>
    <description>Prematurity: birth between 22 and 37 weeks of amenorrhea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the difference in the proportion of late miscarriage between the case group and the control group</measure>
    <time_frame>at childbirth</time_frame>
    <description>late miscarriage: Birth between 14 and 22 weeks of amenorrhea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the difference in the proportion of fetal death in utero between the case group and the control group</measure>
    <time_frame>at childbirth</time_frame>
    <description>fetal death in utero : Negative cardiac activity in utero between 14 weeks and before childbirth</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the difference in the proportion of preeclampsia between the case group and the control group</measure>
    <time_frame>at childbirth</time_frame>
    <description>preeclampsia: Arterial hypertension&gt; 140 and / or 90 mmHg and proteinuria / 24h&gt; 0.3g / 24h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the difference in the proportion of bleeding from delivery between the case group and the control group between the case group and the control group</measure>
    <time_frame>at childbirth</time_frame>
    <description>bleeding from delivery: Blood loss&gt; 500 mL in immediate postpartum up to 2 hours postpartum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the difference in the proportion of small weight for gestational age between the case group and the control group between the case group and the control group</measure>
    <time_frame>at childbirth</time_frame>
    <description>Birth weight &lt;10th percentile according to Sentinel Network Perinatal Database : AUDIPOG</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">336</enrollment>
  <condition>Dengue</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <description>women who contracted symptomatic dengue fever during pregnancy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>women who did not contract symptomatic dengue fever during pregnancy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>data collection</intervention_name>
    <description>data collection</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Case : Patients who contracted dengue fever during pregnancy Control : Patient who does not&#xD;
        get dengue fever during pregnancy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for the case :&#xD;
&#xD;
          -  Pregnant patients&#xD;
&#xD;
          -  Major&#xD;
&#xD;
          -  Affiliated with social security&#xD;
&#xD;
          -  Symptomatic or pauci-symptomatic dengue&#xD;
&#xD;
          -  Biological confirmation of dengue fever&#xD;
&#xD;
        Inclusion Criteria for the control :&#xD;
&#xD;
          -  Pregnant patients&#xD;
&#xD;
          -  Major&#xD;
&#xD;
          -  Affiliated with social security&#xD;
&#xD;
          -  Asymptomatic&#xD;
&#xD;
        Exclusion Criteria for the 2 group :&#xD;
&#xD;
          -  Multiple pregnancy&#xD;
&#xD;
          -  Patient's refusal&#xD;
&#xD;
          -  Protected persons: person deprived of liberty by judicial or administrative decision,&#xD;
             minor, and person subject to a legal protection measure: guardianship or curators)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lucie AUZANNEAU</last_name>
    <phone>0262359949</phone>
    <phone_ext>+262</phone_ext>
    <email>lucie.auzanneau@chu-reunion.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de la Réunion</name>
      <address>
        <city>Saint-Pierre</city>
        <zip>97448</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie AUZANNEAU</last_name>
      <phone>0262359949</phone>
      <phone_ext>+262</phone_ext>
      <email>lucie.auzanneau@chu-reunion.fr</email>
    </contact>
    <investigator>
      <last_name>Marine LAFONT, PH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>March 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2021</study_first_posted>
  <last_update_submitted>November 3, 2021</last_update_submitted>
  <last_update_submitted_qc>November 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dengue fever ; pregnancy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dengue</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

